Details for Patent: 7,429,578

Title:	Tricyclic inhibitors of poly(ADP-ribose) polymerases
Abstract:	Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. ##STR00001## As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.
Inventor(s):	Webber; Stephen Evan (San Diego, CA), Canan-Koch; Stacie S. (La Jolla, CA), Tikhe; Jayashree (San Diego, CA), Thoresen; Lars Henrik (College Station, TX)
Assignee:	Agouron Pharmaceuticals, Inc. (San Diego, CA) Cancer Research Campaign Technology Limited (London, GB)
Filing Date:	Sep 06, 2005
Application Number:	11/221,245
Claims:	1. A method of potentiating cytotoxicity of a DNA-damaging cytotoxic agent or ionizing radiation, comprising contacting cells with an effective amount of a compound of formula (I): ##STR00136## wherein: R.sup.1 is: H; halogen; cyano; an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; or --C(O)--R.sup.10, where R.sup.10 is: H; an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; or OR.sup.100 or NR.sup.100R.sup.110, where R.sup.100 and R.sup.110 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group R.sup.2 is H or alkyl; R.sup.3 is H or alkyl; R.sup.4 is H, halogen or alkyl; X is O or S; Y is (CR.sup.5R.sup.6)(CR.sup.7R.sup.8).sub.n or N.dbd.C(R.sup.5), where: n is 0 or 1; R.sup.5 and R.sup.6 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; and R.sup.7 and R.sup.8 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; wherein said optional substitutions are selected from the group consisting of hydroxy, F, Cl, I, Br, oxo, alkyl, acyl, sulfonyl, mercapto, nitro, alkylthio, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carboxy, primary amino, secondary amino, tertiary amino, carbamoyl, aryloxy, heteroaryloxy, arylthio, and heteroarylthio; or a pharmaceutically acceptable salt thereof, in combination with the DNA-damaging cytotoxic agent or ionizing radiation. 2. The method of claim 1 wherein in the compound of formula (I) or salt thereof, wherein: Y is (CR.sup.5R.sup.6)(CR.sup.7R.sup.8).sub.n, where: n is 1; R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are H. 3. The method of claim 2 wherein in the compound of formula (I) or salt thereof, wherein: R.sup.1 is 4-methylaminomethyl-phenyl; R.sup.2 is H; R.sup.3 is H; R.sup.4 is 8-fluoro; X is O. 4. The method of claim 1 wherein the compound of formula (I) or salt thereof has a cytotoxicity potentiation activity corresponding to a PF.sub.50 of at least 1.1 in a cytotoxicity potentiation assay. 5. The method of claim 1 wherein the compound of formula (I) or salt thereof has a cytotoxicity potentiation activity corresponding to a PF.sub.50 of from about 1.1 to about 3 in a cytotoxicity potentiation assay.